IPV (Polio) Vaccine
Poliomyelitis · Post-polio syndrome
Poliovirus causes irreversible paralysis by destroying motor neurons in the spinal cord. Before vaccination, polio paralyzed 13,000–20,000 Americans annually. The global eradication campaign has reduced polio to near-zero: wild poliovirus now endemic only in Pakistan and Afghanistan. However, vaccine-derived poliovirus (VDPV) circulates in under-vaccinated communities, including a 2022 New York outbreak that paralyzed an unvaccinated young adult.
Overall Benefit Score
Default scenario · 12-month-old · US community (92% vax rate)
Score for your child →Worth careful consideration. Disease risk in your scenario is lower than average, or the vaccine risk/uncertainty is somewhat higher. Discuss timing and priorities with your provider.
📊 Evidence Scores
Scores computed from peer-reviewed data using VaxFact's evidence model. Based on default scenario (12-month-old, standard US community).
🦠 Disease Burden
Poliovirus causes irreversible paralysis by destroying motor neurons in the spinal cord. Before vaccination, polio paralyzed 13,000–20,000 Americans annually. The global eradication campaign has reduced polio to near-zero: wild poliovirus now endemic only in Pakistan and Afghanistan. However, vaccine-derived poliovirus (VDPV) circulates in under-vaccinated communities, including a 2022 New York outbreak that paralyzed an unvaccinated young adult.
Paralytic polio: irreversible flaccid paralysis of one or more limbs. Bulbar polio: paralysis of breathing muscles requiring iron lung or ventilator. Post-polio syndrome: 25–40% of survivors develop new weakness, fatigue, and pain 15–40 years after initial illness. No treatment for acute paralytic polio — only supportive care.
🛡️ Vaccine Effectiveness
Four doses of IPV provide lifelong immunity against paralytic poliomyelitis. Serum antibody titers remain protective for decades. Adults who completed a childhood series have durable protection. Additional doses are recommended for adults traveling to polio-endemic countries or during outbreak response.
Paralytic polio has not occurred in a fully vaccinated US individual from wild poliovirus. The 2022 New York case occurred in an unvaccinated adult.
⚠️ Adverse Events & Side Effects
All probabilities are per 100,000 doses administered, sourced from VAERS, Vaccine Safety Datalink, and post-licensure surveillance studies.
Common Side Effects
Rare Serious Events
📅 Vaccine Schedule
Unvaccinated children/adults: 3-dose catch-up series. Travel to endemic areas (Pakistan, Afghanistan): booster dose recommended for adults who completed childhood series >10 years ago.
⚖️ Benefits vs. Considerations
✓ Benefits
- Near-miraculous success: eliminated paralytic polio from the US — from 20,000 cases/year to near zero
- Among the safest vaccines ever developed — adverse event profile essentially limited to mild injection site reactions
- 70 years of post-licensure data across billions of doses
- Lifelong protection from 4 doses
- Prevents irreversible paralysis — no treatment exists once paralysis occurs
- IPV (unlike OPV) cannot cause vaccine-associated paralytic polio
↕ Considerations
- IPV provides weaker intestinal (mucosal) immunity than OPV — vaccinated individuals can still carry poliovirus and potentially spread it in under-vaccinated communities
- Requires injection (vs. oral drops for OPV used globally)
- 4-dose schedule requires multiple healthcare visits
- Global eradication relies on OPV campaigns, not just IPV — a complex dual-vaccine world
🔬 What Some Researchers Question
These are legitimate scientific debates — not fringe claims. They represent areas of ongoing research or policy disagreement among credentialed experts.
- The switch from OPV to IPV in high-income countries has created a two-tier global polio vaccination system: high-income countries use IPV (safer, no VDPV risk) while low-income countries continue to rely on OPV (which can generate circulating vaccine-derived poliovirus in under-vaccinated communities). Some researchers argue the persistence of VDPV outbreaks — now more common than wild polio — is partly a consequence of incomplete global IPV transition funding (Bandyopadhyay et al., 2015).
- The 2022 New York VDPV case that paralyzed an unvaccinated young adult revealed that the sewage surveillance system had detected poliovirus in wastewater for months before the case — raising questions about the adequacy of surveillance and outbreak response in communities with declining vaccination rates in the US.
🌫️ Scientific Uncertainties
Honest acknowledgment of what we don't yet know with confidence.
- How long the US can maintain polio-free status given vaccine-derived poliovirus (VDPV) circulation in under-vaccinated communities globally and domestically
- Whether the 2022 New York VDPV case represents an isolated event or a harbinger of sustained community spread in under-vaccinated areas
- Long-term strategy as global eradication approaches — when to transition away from any polio vaccination
🌍 International Policy Comparison
How different countries approach this vaccine — revealing where global consensus is strong vs. where policy diverges.